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Background: Anemia is a common condition in CKD that has been identified as a cardiovascular (CV) risk factor in
end-stage renal disease, constituting a predictor of low survival. The aim of this study was to define the onset of
anemia of renal origin and its association with the evolution of kidney disease and clinical outcomes in stage 3 CKD
(CKD-3).
Methods: This epidemiological, prospective, multicenter, 3-year study included 439 CKD-3 patients. The origin of
nephropathy and comorbidity (Charlson score: 3.2) were recorded. The clinical characteristics of patients that
developed anemia according to EBPG guidelines were compared with those that did not, followed by multivariate
logistic regression, Kaplan-Meier curves and ROC curves to investigate factors associated with the development of
renal anemia.
Results: During the 36-month follow-up period, 50% reached CKD-4 or 5, and approximately 35% were diagnosed
with anemia (85% of renal origin). The probability of developing renal anemia was 0.12, 0.20 and 0.25 at 1, 2 and 3
years, respectively. Patients that developed anemia were mainly men (72% anemic vs. 69% non-anemic). The mean
age was 68 vs. 65.5 years and baseline proteinuria was 0.94 vs. 0.62 g/24h (anemic vs. non anemic, respectively).
Baseline MDRD values were 36 vs. 40 mL/min and albumin 4.1 vs. 4.3 g/dL; reduction in MDRD was greater in those
that developed anemia (6.8 vs. 1.6 mL/min/1.73 m2/3 years). These patients progressed earlier to CKD-4 or 5 (18 vs.
28 months), with a higher proportion of hospitalizations (31 vs. 16%), major CV events (16 vs. 7%), and higher
mortality (10 vs. 6.6%) than those without anemia. Multivariate logistic regression indicated a significant association
between baseline hemoglobin (OR=0.35; 95% CI: 0.24-0.28), glomerular filtration rate (OR=0.96; 95% CI: 0.93-0.99),
female (OR=0.19; 95% CI: 0.10-0.40) and the development of renal anemia.
Conclusions: Renal anemia is associated with a more rapid evolution to CKD-4, and a higher risk of CV events and
hospitalization in non-dialysis-dependent CKD patients. This suggests that special attention should be paid to
anemic CKD-3 patients.
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Chronic kidney disease (CKD) is a highly prevalent dis-
ease frequently associated with diabetes and high cardio-
vascular (CV) risk. This combination results in a
considerable mortality rate [1,2]. The prevalence of CKD
stages 3–5 is 6.8% in Spain [3]. Anemia is common in
CKD and has been linked to cardiovascular disease and
mortality [2]. According to THE European Best Practice
Guidelines (EBPG) published in 2004, a diagnosis of
anemia is considered to be a hemoglobin concentration
(Hb) of less than 11.5 g/dL in women, < 12 g/dL in men
aged > 70 years, or < 13.5 g/dL in men aged ≤ 70 years
[4]. Renal anemia in CKD is largely due to a deficiency
in renal production of erythropoietin, usually being nor-
mocytic and normochromic, although its appearance has
been also associated to iron deficiency [5], and several
retrospective studies have reported a higher prevalence
of anemia when inflammatory processes, malnutrition or
diabetes are present in severe CKD [1,3,6,7].
The development of anemia is expected in CKD stages
3 to 5, but onset varies from one patient to another. A
large cohort study performed between 1988 and 1994
reported a prevalence of renal anemia of 1% in CKD
stage 3, 9% in stage 4 and over 33% in stage 5 [8]. Later
studies reported higher values (5% for CKD-3 and 55%
for CKD-4) [9,10].
On the other hand, CKD-3 patients may be asymp-
tomatic, especially in the absence of anemia or other
complications. Many are not referred to nephrologists
and, therefore, little is known of their characteristics and
evolution. Moreover, most studies on the prevalence of
anemia are cross-sectional and do not establish the
onset and evolution of anemia. Therefore, the primary
objective of this study was to determine the time course
of the clinical evolution of stage 3 CKD patients, to esti-
mate the incidence of anemia of renal origin and to de-
scribe its characteristics.
Methods
The NADIR-3 study (Study of non-anemic stage 3 CKD
patients who develop renal anemia) is a longitudinal,
prospective, multicenter study conducted in Spain. It
was promoted by the Spanish Group for the Study of
Diabetic Nephropathy (GEENDIAB by its Spanish initi-
als) and the Strategic Action Plan of the Spanish Society
of Nephrology. The study was performed with the ap-
proval of the reference Ethics Committee for Clinical
Research of the La Paz University Hospital (Madrid),
and this approval was accepted by the authorities of the
other participating centers. All procedures were in com-
pliance with the Declaration of Helsinki.
Based on the incidence of anemia and the dropout rate
reported in previous studies, a minimum sample size of
427 patients was considered to estimate the anemiaonset rate with a 95% precision. Recruitment of patients
was performed by participant nephrologists between Oc-
tober 2005 and March 2006 and written consent was
obtained from all participants. Clinical assessment was
undertaken and blood samples of patients were obtained
consecutively every 6 months for 36 months after enroll-
ment, or until the initiation of dialysis or renal trans-
plant (RRT). Exclusion criteria were; transfusions within
three months of entry, treatment with erythropoiesis
stimulating agents (ESA), prior kidney transplant, or
treatment with immunosuppressive drugs. Inclusion cri-
teria were; subjects between the ages of 18 and 78 years,
with MDRD estimated glomerular filtration rates (eGFR)
≥ 30and < 60 mL/min, without anemia. Anemia was
defined by the following criteria: Hb concentration
below 11.5 g/dl in women, Hb below 12.0 g/dl in men
aged 70 years and over, and Hb below 13.5 g/dl in men
younger than 70 years of age, as stated by the EBPG
guidelines [4]. The onset of anemia (anemia primary end-
point) was established as the detection of Hb concentra-
tions below the mentioned levels at any time, and this was
confirmed by a second test performed 15 days later.
Baseline clinical and biochemical data, as well as treat-
ment information was obtained during the first visit and
follow-up data were obtained every six months until
completion of a 36–month follow-up period. All data
were included in an electronic CRF. Recorded demo-
graphic, clinical and biochemical data included age; gen-
der; etiology of renal disease; time from CKD-3 diagnosis;
smoking habits; weight; height; body mass index (BMI);
medications; blood pressure (BP); serum values of glucose,
lipid profile, total plasmatic proteins, albumin, urea, uric
acid, creatinine, potassium, bicarbonate, calcium, phos-
phate, parathyroid hormone (PTH), alkaline phosphatase,
C-reactive protein (CRP), homocysteine, ferritin, transfer-
rin saturation index, folic acid, and vitamin B12; CBC;
24-hour diuresis; urine urea and proteinuria. Glomeru-
lar filtration was estimated using the MDRD-4 formula,
based on non-standardized serum creatinine values in
each center.
The development of anemia was continuously recorded,
including an exhaustive clinical study to identify the cause
of its appearance as suggested by clinical guidelines [4].
Anemia of renal origin was established once other possible
causes of anemia were excluded (episodes of bleeding, sur-
gery, chronic inflammation, myelodysplasic syndrome,
tumors, folic acid or vitamin B12 deficit, other minor
causes). Onset of anemia was analyzed in fixed annual
periods and events (hospital admissions, death) were con-
sidered only after the onset of anemia in order to analyze
the possible association. This allowed for the establish-
ment of a logical link provided by timing.
Patients were instructed to contact their nephrologist
if any Hb value under the aforementioned anemia limits
Figure 1 Flowchart of subjects included in the study.
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study period, including tests ordered for other reasons
or by other physicians. Likewise, a note to the primary
care physician was included in every clinical report
handed to the patients. Supervening events as
hospitalization, the initiation of RRT, major CV events,
or death were also recorded throughout the study. As a
secondary objective, we included a descriptive analysis of
these events and the factors related with their appear-
ance. Comorbidities at the time of inclusion were calcu-
lated by the Charlson comorbidity index [11,12].
Diabetes and dyslipidemia were diagnosed according to
the American Diabetes Association and the National
Cholesterol Education Program criteria.
Data were analyzed using the SPSS 12.0 statistical
package (SPSS Inc., Chicago, Illinois, USA). Categorical
variables are presented as the number of observations
(n) and percentages. Continuous variables are expressed
as mean and standard deviation (SD) unless otherwise
indicated. Comparisons between categorical variables
were analyzed with the χ2 test or the Z-test. Continuous
variables were compared using parametric or non-
parametric tests as appropriate (t-test or one-way
ANOVA if parametric, Wilcoxon signed rank sum test
or ANOVA if non-parametric). ROC curves were per-
formed to analyze the specificity and sensitivity of the
development of anemia as a prognostic factor in CKD.
Time to onset of anemia (primary event) was calculated
using Kaplan-Meier curves. Spearman’s rank-order cor-
relation coefficient and multivariate logistic regression
analysis were used to examine the relationship between
baseline status (renal disease, Hb, comorbidities) and the
development of anemia. Survival analysis was adjusted
for competing risks (death, renal transplant and patient
drop out prior to the development of anemia) to avoid
overestimation of risk. For all analyses, a P-value < 0.05
was deemed statistically significant.
Results
Twenty-seven nephrology departments in Spanish hospi-
tals participated in the NADIR-3 study. Four hundred
and thirty nine patients meeting inclusion criteria were
enrolled. Figure 1 shows the patient flowchart.
Baseline characteristics of participants
Table 1 summarizes the demographic and laboratory
data of the patients included. Etiology of renal disease
was: vascular nephropathy (28.4%), disease of unknown
etiology (18.0%), diabetic nephropathy (17.0%), glomeru-
lar (12.3%), interstitial (10.4%), or polycystic disease
(7.2%) and disease of other origin (6.7%). Most patients
(78.0%) were referred to nephrologists or had been diag-
nosed in the 5 years prior to recruitment. Estimated
glomerular filtration rate was calculated using theabbreviated MDRD method (eGFR), and baseline values
were 39.1 ± 9.1 mL/min. Hemoglobin mean value (Hb)
was 14.3 ± 1.3 g/dl (range 11.6-20.4) per inclusion cri-
teria, and was higher in men than in women (14.7 g/dl
[range 12.0-20.4] vs. 13.3 g/dl [range 11.6-16.4], respect-
ively). In men ≥ 70 years, mean baseline Hb was 14.3 g/dl
(range 12.0-18.3), which was lower than in younger men
(14.9 g/dl [range 13.5-20.4]). Baseline eGFR and Hb values
did not correlate in women and in men ≥ 70 years, while
there was a significant correlation in men younger than 70
years of age (p< 0.01).
Most patients (92.8%) presented with hypertension
and approximately one third (32.8%) were diabetic at the
time of inclusion. Charlson Comorbidity Index (CCI) at
baseline was 3.22 ± 1.58 (range 2–12; median 3.00).
None of the patients presented with a history of bleeding
events.
Evolution of renal function and associated disease
conditions
The eGFR decline rate was 1.1 mL/min per year and the
mean value at the end of study was 36.0 ± 12.3 mL/min
vs. 39.1 ± 9.1 mL/min at the time of inclusion. As per in-
clusion criteria, all the patients presented CKD-3 at
baseline, and 173 patients were diagnosed CKD stage 4
or 5 during the 36 month duration of the study. Kaplan-
Meier analysis showed an estimated survival time of
25.4 ± 0.7 months until stage 4–5 (Figure 2B). Protein-
uria was also significantly reduced at the end of the
follow-up period (0.69 ± 1.00 g/24h vs. 0.52 ± 0.80 g/24 h,
p< 0.05). The proportion of patients meeting the criterion
of relevant proteinuria (> 1.0 g/24 h) decreased from
20.4% to 15.1%, but the difference was not significant
(p=0.114). No changes in mean blood pressure (systolic,
diastolic and pulse) were observed, and the distribution of
patients according to blood pressure targets did not vary
(data not shown). Similarly, the proportion of patients
Table 1 CKD-3 patient baseline characteristics classified by the development or not of renal anemia
Total Non-anemic
patients n = 242
Anemic patients
n = 102
Statistical
significance
Gender Female [n (%)] 122 (30.1%) 93 (30.7%) 29 (28.4%) 0.976
Age (years) Median (range) 67 (22–78) 68 (22–78) 65 (24–78) 0.115
Time from CKD diagnosis (years) Mean (SD) 4.1 (4.8) 3.9 (4.8) 4.7 (4.9) 0.119
Smoking [n, (%)] Smokers 41 (10.1%) 28 (9.2%) 13 (12.7%) 0.427
Ex-smokers 158 (39.0%) 116 (38.3%) 42 (41.2%)
BMI (Kg/m2) Mean (SD) 28.0 (4.1) 27.9 (3.9) 28.5 (4.6) 0.260
Blood pressure (mmHg) Systolic [mean (SD)] 134.3 (16.0) 133.8 (15.7) 135.7 (16.8) 0.302
Diastolic [mean (SD)] 76.3 (10.2) 75.6 (9.8) 78.5 (10.8) 0.013
MDRD-eGFR (mL/min) Mean (SD) 39.1 (9.1) 40.1 (9.3) 35.9 (7.9) 0.000
uProtein (g/24 h) Mean (SD) 0.7 (1.1) 0.6 (0.9) 1.0 (1.4) 0.011
Serum Albumin (g/dL) Mean (SD) 4.3 (0.4) 4.1 (0.4) 4.3 (0.3) <0.001
Corrected Calcium (mEq/L) Mean (SD) 9.4 (0.5) 9.4 (0.5) 9.5 (0.43) 0.005
Phosphate (mg/dl) Mean (SD) 3.4 (0.7) 3.4 (0.7) 3.7 (0.6) 0.000
PTH (pg/ml) Mean (SD) 95.9 (63.8) 91.9 (50.3) 107.4 (92.0) 0.181
CRP (mg/dl) Mean (SD) 2.1 (3.0) 2.2 (3.0) 1.7 (2.9) 0.143
Ferritin (ng/dl) Mean (SD) 131.8 (0.6) 128.9 (93.4) 139.6 (104.9) 0.365
Transferrin saturation index (%) Mean (SD) 30.2 (31.1) 31.4 (35.9) 26.9 (8.0) 0.278
Folic acid (ng/mL) Mean (SD) 8.7 (3.6) 8.6 (3.6) 9.0 (3.7) 0.434
Vitamin B12 (pg/mL) Mean (SD) 501.6(196.2) 495.1 (197.5) 518.9 (193.1) 0.347
Hb (g/dl) Mean (SD) 14.2 (1.7) 14.0 (1.3) 13.7 (2.5) 0.000
Medications Antihypertensives [n (%)] 378 (93.3%) 278 (91.7%) 100 (98.0%) 0.028
Anticoagulant / antiplatetet [n (%)] 31 (7.7%) 27 (8.9%) 4 (3.9%) 0.101
Glucose lowering agents [n (%)] 117 (28.9%) 88 (29.0%) 29 (28.4%) 0.906
Lipid lowering agents [n (%)] 242 (59.8%) 180 (59.4%) 62 (60.8%) 0.806
Mineral bone treatment [n (%)] 41 (10.1%) 30 (9.9%) 11 (10.8%) 0.798
Others [n (%)] 154 (39.5%) 120 (41.2%) 34 (34.3%) 0.225
Data are mean (standard deviation) or median and range, as indicated. n = number of patients. BMI: Body Mass Index. MDRD-eGFR: estimated glomerular filtration
rate calculated with the abbreviated MDRD equation. CKD: Chronic kidney disease. PTH: parathyroid hormone. CRP: C-reactive protein. Hb: Hemoglobin.
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during the study period (95.4% vs. 96.3% at 36 months),
although the average number of anti-hypertensive med-
ications used increased in the same period (2.2 to 2.4
per patient). No variation in the proportion of patients on
treatment with angiotensin-converting enzyme inhibitors
was observed, while the proportion of patients using
angiotensin II receptor antagonists slightly increased
(54% vs. 48%).
None of the patients displayed malnutrition, defined as
BMI < 20 and albumin < 3.5 g/dl, at any time point. Mean
BMI did not change significantly (data not shown), and
there was a small but significant decrease of serum albumin
concentration from 4.3 ± 0.4 to 4.2 ± 0.4 g/dl (p< 0.005).
Twenty-two patients developed de novo diabetes dur-
ing the follow-up period. Although the mean concentra-
tion of serum glucose and glycosylated Hb values did
not change with time, there was a reduction in theproportion of patients with glycosylated Hb values below
7.5% (79.8% compared to 69.7% at baseline; p< 0.001).
Time course of hemoglobin concentration changes and
onset of renal anemia
At the end of the 3-year follow-up period, 120 patients
developed anemia. Anemia appeared after hemorrhage
in 8% of these patients, after surgery in 3%, and after a
diagnosis of neoplasia in 1%; less than 1% were diagnosed
with megaloblastic anemia. Anemia of other origin was
reported in 3%. The rest (85%, n=102) were diagnosed
with renal anemia according to the established criteria.
Onset of renal anemia varied with time: 34 patients were
diagnosed at 6 months; 14 at 12 months; 18 at 18 months;
14 at 24 months; 10 at 30 months and 12 at 36 months.
The mean time from inclusion until diagnosis of renal
anemia, in those patients who developed it, was 16.8 ± 10.2
months (range 2.9-35.9). Patients with renal anemia who
Figure 2 Survival distribution function according to: A. Time to
development of anemia (competing risk model with death and
RRT). B. Evolution to CKD-4 or CKD-5 for all the CKD-3 patients
included in the study (Kaplan-Meyer). C. Evolution to CKD-4 or −5
for patients that developed renal anemia (Yes) and the non-anemic
patients (No) (Kaplan-Meyer). See text for details.
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erythropoietic stimulating agents (27.3% of anemic patient
at 36 months). Use of iron therapy increased progressively
to 21% at the end of follow-up. Only 13 patients were on
ESA treatment for more than one year. ESA treatment did
not have any effect on patient outcome (data not shown)
possibly due to the low percentage of patients receiving
treatment and for short times. Although treatment of
anemia and analysis of the degree of target fulfillment were
not among our objectives, it should be emphasized that
there is a wide margin between the definition of anemia
and the level of Hb where treatment with ESAs should
be started. Therefore, the low percentage of patients
treated with ESAs cannot be interpreted as “therapeutic
nihilism”.
Kaplan-Meier analysis was performed to estimate the
onset of renal anemia. The incidence rate was about 9
cases per 1000 patient-months and the estimated mean
survival time until anemia onset (i. e., time in which the
probability of developing anemia reaches 50% for all
patients) was 34.1 ± 0.7 months, 95% CI [32.7-35.4].
Since this event did not reach 50% at the time of study
closure, the time median could not be estimated. A sur-
vival analysis plot adjusted for competing risks (exitus,
renal transplant and patient drop out before anemia de-
velopment) was used to avoid overestimation of the inci-
dence of anemia (Figure 2A). The estimated annual rate
of onset of renal anemia was 0.11 in the first year, 0.20
in the second year and 0.26 in the third year,
Clinical factors associated with the development of renal
anemia and the evolution of anemic and non-anemic
patients
Table 1 shows the characteristics of patients that devel-
oped renal anemia during the 36-month follow-up
period (anemic patients) and those that did not (non-
anemic patients). Baseline clinical and analytical data
were compared. As can be observed, baseline values of
proteinuria and serum albumin were significantly differ-
ent between patients with and without anemia. Similarly,
baseline MDRD-eGFR was significantly lower in anemic
patients than in non-anemic patients. Table 2 shows the
main clinical events and outcomes in patients classified
according to the onset of anemia.
Performance of multivariate logistic regression analysis
to identify factors related to the development of anemia
led to a best model that included baseline eGFR,
Table 2 Main clinical evolution parameters in patients
who developed renal anemia vs. non-anemic patients
Non-anemic
patients
Anemic
patients
p-value
Mortality 6.6% 10.3% p<0.005
Annual hospitalization rate 16.1% 31.4% p<0.001
Major CV events 7.2% 16.4% p<0.01
Δ MDRD (mL/min/3 years) −1.6 −6.8 p<0.001
Reached CKD 4-5 32.8% 74.3 % p<0.001
Δ MDRD: difference in estimated glomerular filtration rate calculated with the
abbreviated MDRD equation. CDK: Chronic kidney disease.
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anemia increased 2.88-fold with each reduction of 1 g/dl
in the initial Hb concentration increased 1.04-fold per
each reduction of 1 mL/min in the eGFR-MDRD value
was 5.05 times higher for male subjects (OR=0.198; p<
0.001) (Table 3). Baseline proteinuria and comorbidities
did not enhance the predictive value of this model. ROC
curves were generated considering this 3-variable model
and specificity of 92.3%, sensitivity of 34.7% and area
under the curve 0.792 (0.741-0.843) were obtained (Fig-
ure 3). The low sensitivity value indicates that the math-
ematical model appropriately discriminates non-anemic
patients only.
The incidence of hospitalizations during the follow-up
was 16.1% in non-anemic patients, the median number
of hospitalizations per patient being 1 (range 1–2), and
the median number of days in the hospital being 5
(range 1–36) . The main reason for hospital admission
in non-anemic patients was surgery, followed by infec-
tion, peripheral vascular disease, angina, and other CV
events. The frequency of hospital admissions was signifi-
cantly higher (31.4% vs. 16.1%; p< 0.001) in anemic
patients, the median number of hospitalizations per pa-
tient being one (maximum 3) and the median number of
days in the hospital 10 (range 2–36). The most common
reason in these patients was congestive cardiac failure,
followed by infection, surgery, peripheral vascular dis-
ease, and other cardiovascular events. In the anemic
group, the incidence of major CV events after three
years of follow-up was significantly higher (Table 2).
These results support the idea that development of
anemia CKD-3 is associated to a more rapid evolution of
clinical condition.Table 3 Risk factors for renal anemia development. Odds rati
regression
B
Basal Hb value (per ↑ 1 g/dl) −1.06
Basal eGFR MDRD (per ↑ 1 mL/min) −0.04
Female vs. Male −1.62
MDRD-eGFR: estimated glomerular filtration rate calculated with the abbreviated MAs stated above, 173 patients reached stages 4 or 5
during the study. Of these, 75 developed renal anemia
(74.3% of all anemic patients) and 78 did not (32.2% of
all non-anemic patients) (Table 2). Survival analysis
showed significant differences between both groups
(Figure 2C). The average estimated time to reach CKD-4
or CKD-5 was 28.2 ± 0.8 months for non-anemic patients
and 18.0 ± 1.3 months for anemic patients, and the differ-
ence between these values was significant (p< 0.001).
Quicker progression of renal disease was found be-
tween groups when the decrease of eGFR was compared
(−6.8 ml/min/36 months vs. −1.6 mL/min/36 months;
p< 0.001). Despite the greater reduction in eGFR found
in anemic patients, the decrease in proteinuria over the
follow-up period was slightly lower in anemic patients
(20.9% vs. 29.1%, p=0.240). The quicker decrease of
eGFR and the shorter time to reach CKD-4 or −5 sug-
gested that development of renal anemia could be a surro-
gate marker indicating faster progression of kidney disease.
Discussion
Anemia is a well-known complication of CKD but there
is controversial information about its onset, morbidity
and relevance as a prognostic factor in stage 3 CKD.
The present longitudinal study included more than 400
CKD-3 patients that were non-anemic at baseline. Diag-
nosis of anemia in this CKD-3 group increased with
time, approaching 35% at 36 months. Previous epi-
demiological studies established a prevalence of anemia
of around 5% in CKD-3 and 45% in CKD-4 stages
[8,10,13]. However, most of these studies included
patients in different CKD stages who were often subject
to dialysis or transplant, or were single-center studies
with a low number of participants. The prevalence of
anemia at the end of the follow-up period in our cohort
was only slightly lower than that previously reported in
transversal studies, but comparison is difficult due to the
significant differences in study design and patient popu-
lations. A previous preliminary interim analysis of this
study showed that 12.4% of patients developed anemia
during the first year of follow-up [14]. In this final ana-
lysis, prevalence increased by about 10% per year in a
real setting of follow-up in nephrology services, and was
accompanied by renal function decline of 1.1 mL/min
per year. To our knowledge, this is the first prospectiveo (OR) values for multivariate backward step logistic
P value OR 95% CI
0.000 0.347 [0.253 - 0.475]
0.012 0.961 [0.931 - 0.99]
0.000 0.198 [0.099 - 0.399]
DRD equation. Hb: Hemoglobin.
Figure 3 Receiver operator characteristic (ROC) curve showing
the sensitivity and specificity of the model incorporating eGFR,
HB and gender to predict development of anaemia within the
3-year follow-up period.
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3 patients.
CKD-3 patients that developed anemia in our cohort
had a significant increase of risk of hospital admission,
CV events and mortality when compared to non-anemic
CKD-3 patients. We also observed that a quicker decrease
in the eGFR and increased proteinuria were associated
with the development of anemia, and this condition has
been associated with increased morbidity and mortality in
CKD patients [1,2,15,16]. Two studies performed with
young CKD-3 to CKD-5 patients showed that anemia is
associated with diminished quality of life, increased fre-
quency of hospitalization and higher risk of mortality
[15,17], while another did not find any association be-
tween anemia and increased hospitalization [18]. These
controversial results may be due to different patient char-
acteristics, comorbidity, CKD stages of the cohort, sample
sizes or anemia definitions. The lack of consistency in the
results between these studies emphasizes the importance
of studying homogeneous groups of patients and, in par-
ticular, the need to describe “predialysis CKD patients”
separately from those that receive renal replacement ther-
apy. This has been one of the objectives of the present
work. Our results indicate a poorer prognosis for patients
who develop anemia. There is a possibility that anemia, even
anemia of renal origin, acts as a surrogate marker for other
conditions associated to increased risk of hospitalization,
that is, other underlying diseases or chronic inflamma-
tion, that have been associated with anemia in CKDpatients [19,20]. This possibility should be investigated
in further studies. In the present study, the most com-
mon cause for hospitalization in anemic patients was
congestive heart failure, which could be due to the
additive effect of anemia on the cardiac condition
caused by hypertension, which was present in almost
all the participants [21] .
A recent prospective study including more than 600
anemic and non-anemic CKD patients classified them in
four categories (non-anemic, mild anemic with corrected
anemia, persistent mild anemic or progression to severe
anemia), and the last two groups showed higher risk for
progression to end-stage renal disease or death. [22]
Previous studies have also reported the association be-
tween anemia and CKD stage [2,7-10,13,23-26]. Simi-
larly, our results showed decreased kidney function in
anemic patients compared to non-anemic participants,
as revealed by the faster decrease of GFR and, conse-
quently, the shorter time to reach stages CKD-4 or
CKD-5. It not possible to determine which is the first
event, anemia or CKD progression, but the present
results suggest that anemia may be a potential marker
for faster progression of CKD, and for the probability of
hospitalization and major CV events. In the present
series, those patients that did not develop anemia
showed better clinical evolution, associated with a slower
progression of CKD as well as lower rates of mortality
and relevant clinical complications.
Several previous reports indicated the association of
baseline eGFR, proteinuria, greater age and male gender
with a higher prevalence of anemia [13,23,25,26]. We
have found that patients that developed anemia had sig-
nificantly lower baseline eGFR and higher proportion of
significant proteinuria (>1 g/24h) [10,14]. However, pro-
teinuria did not have prognostic value in the multivariate
model including initial eGFR, Hb, and gender. This sug-
gests a need for closer follow-up of non-anemic CKD-3
patients with high proteinuria and progression of CKD
in order to detect renal anemia onset early and eventu-
ally adjust treatment.
Although the number of participants in our study was
sufficient, some limitations should be commented: Firstly,
the observational design does not allow for the establish-
ment of causality between the onset of anemia and poor
outcomes; Secondly, selection bias in our cohort is pos-
sible, since inclusion depended on patient acceptance; and
thirdly, the study lacked a consensus protocol for starting
dialysis, so we could not consider it as an event. Finally, al-
though data on the onset of anemia was collected at a pre-
cise time point, other data were collected at 6-month
intervals, and the results obtained from time-dependent
analysis should be interpreted cautiously. However, the
resulting cohort was in accordance with the sample-size
estimation and presented great homogeneity, probably
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CKD-3 patients have been studied.
Conclusions
In summary, we have estimated the timing and rate for
the onset of anemia in CKD-3 patients in a specific 3-
year prospective study using a competing risk model.
The probability of developing anemia was higher for
men, those of older age, lower baseline eGFR and higher
proteinuria levels. Only some patients who developed
anemia reached the Hb level necessary to be eligible for
treatment with ESAs. Anemia was also associated with
a rapid decline of renal function, increased risk of
hospitalization and increased mortality. Those CKD-3
patients who did not develop anemia presented rela-
tively good prognoses and better outcomes. The
present overall results suggest that the onset of anemia
in CKD stage 3 distinguishes two types of patients with
different clinical evolutions, which may help to estab-
lish different health strategies for these patients.
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